{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T15:18:46Z","timestamp":1791213526215,"version":"4.1.0"},"reference-count":252,"publisher":"American Association for the Advancement of Science (AAAS)","issue":"23","content-domain":{"domain":["www.science.org"],"crossmark-restriction":true},"short-container-title":["Sci. Adv."],"published-print":{"date-parts":[[2025,6,6]]},"abstract":"<jats:p>\n            Several landmark studies over the past decade have uncovered a critical role of the CRL3\n            <jats:sup>KBTBD4<\/jats:sup>\n            ubiquitin ligase complex in regulating stability of corepressor of repressor element 1 silencing transcription factor (CoREST) complex proteins and normal hematopoietic stem cell self-renewal. There is now mounting evidence that the CoREST complex plays oncogenic roles, although the contributions of its catalytic versus noncatalytic functions remain unclear. Here, we summarize and discuss mechanisms whereby the CoREST complex coopts tissue-specific transcription factors to elicit pathogenic activity in cancer and neurodegenerative disease. We also identify tumor types with selective dependencies on the scaffolding properties of the CoREST complex. We argue that these tumor types may benefit from a KBTBD4-activating\/CoREST complex degrader therapy, which could also enhance antitumor immunity and sensitize resistant tumors to immunotherapy. Overall, understanding how the CoREST complex operates abnormally and differences between its targeting through catalytic inhibitors or protein degraders will help discern all possible applications for targeting therapies now in clinical development.\n          <\/jats:p>","DOI":"10.1126\/sciadv.ads6556","type":"journal-article","created":{"date-parts":[[2025,6,6]],"date-time":"2025-06-06T17:58:24Z","timestamp":1749232704000},"update-policy":"https:\/\/doi.org\/10.34133\/aaas_crossmark","source":"Crossref","is-referenced-by-count":10,"title":["CoREST in pieces: Dismantling the CoREST complex for cancer therapy and beyond"],"prefix":"10.1126","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4791-5083","authenticated-orcid":true,"given":"Houssam","family":"Ismail","sequence":"first","affiliation":[{"name":"Institute for Research in Immunology and Cancer (IRIC), Universit\u00e9 de Montr\u00e9al, Montr\u00e9al, Qu\u00e9bec, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jalila","family":"Chagraoui","sequence":"additional","affiliation":[{"name":"Institute for Research in Immunology and Cancer (IRIC), Universit\u00e9 de Montr\u00e9al, Montr\u00e9al, Qu\u00e9bec, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4333-7266","authenticated-orcid":true,"given":"Guy","family":"Sauvageau","sequence":"additional","affiliation":[{"name":"Institute for Research in Immunology and Cancer (IRIC), Universit\u00e9 de Montr\u00e9al, Montr\u00e9al, Qu\u00e9bec, Canada."},{"name":"Department of Medicine, Universit\u00e9 de Montr\u00e9al, Montr\u00e9al, Qu\u00e9bec, Canada."},{"name":"Division of Hematology, Maisonneuve-Rosemont Hospital, Montr\u00e9al, Qu\u00e9bec, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"221","reference":[{"key":"e_1_3_1_2_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrd2133"},{"key":"e_1_3_1_3_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1321330111"},{"key":"e_1_3_1_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/0092-8674(95)90298-8"},{"key":"e_1_3_1_5_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.7871435"},{"key":"e_1_3_1_6_2","doi-asserted-by":"publisher","DOI":"10.1038\/nature04021"},{"key":"e_1_3_1_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0896-6273(01)00371-3"},{"key":"e_1_3_1_8_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.1076469"},{"key":"e_1_3_1_9_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M109.038356"},{"key":"e_1_3_1_10_2","doi-asserted-by":"publisher","DOI":"10.1039\/D1MO00236H"},{"key":"e_1_3_1_11_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0007936"},{"key":"e_1_3_1_12_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0007665"},{"key":"e_1_3_1_13_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0906917107"},{"key":"e_1_3_1_14_2","doi-asserted-by":"publisher","DOI":"10.1128\/MCB.00083-14"},{"key":"e_1_3_1_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2004.12.012"},{"key":"e_1_3_1_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.molcel.2005.08.027"},{"key":"e_1_3_1_17_2","doi-asserted-by":"publisher","DOI":"10.1128\/MCB.00723-06"},{"key":"e_1_3_1_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2020.01.091"},{"key":"e_1_3_1_19_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1404292111"},{"key":"e_1_3_1_20_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-29261-0"},{"key":"e_1_3_1_21_2","doi-asserted-by":"publisher","DOI":"10.1042\/BCJ20170314"},{"key":"e_1_3_1_22_2","doi-asserted-by":"publisher","DOI":"10.1093\/jmcb\/mjy021"},{"key":"e_1_3_1_23_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3091"},{"key":"e_1_3_1_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2009.05.050"},{"key":"e_1_3_1_25_2","doi-asserted-by":"publisher","DOI":"10.1038\/nbt.1759"},{"key":"e_1_3_1_26_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-17078-8"},{"key":"e_1_3_1_27_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.1256337"},{"key":"e_1_3_1_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.stem.2020.12.002"},{"key":"e_1_3_1_29_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020005827"},{"key":"e_1_3_1_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbc.2023.104662"},{"key":"e_1_3_1_31_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-024-08532-4"},{"key":"e_1_3_1_32_2","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2019-4718"},{"key":"e_1_3_1_33_2","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2023-ND12"},{"key":"e_1_3_1_34_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1097-2765(02)00741-4"},{"key":"e_1_3_1_35_2","doi-asserted-by":"publisher","DOI":"10.1101\/gad.9.14.1753"},{"key":"e_1_3_1_36_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1074-7613(00)80238-1"},{"key":"e_1_3_1_37_2","doi-asserted-by":"publisher","DOI":"10.1093\/emboj\/17.13.3714"},{"key":"e_1_3_1_38_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2012.03.014"},{"key":"e_1_3_1_39_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-016-0252-7"},{"key":"e_1_3_1_40_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1535-6108(02)00018-1"},{"key":"e_1_3_1_41_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0900437106"},{"key":"e_1_3_1_42_2","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2012.8"},{"key":"e_1_3_1_43_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-11-610907"},{"key":"e_1_3_1_44_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.1102160"},{"key":"e_1_3_1_45_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-0919"},{"key":"e_1_3_1_46_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.molcel.2007.06.039"},{"key":"e_1_3_1_47_2","doi-asserted-by":"publisher","DOI":"10.1242\/jcs.095877"},{"key":"e_1_3_1_48_2","doi-asserted-by":"publisher","DOI":"10.1038\/ncb3276"},{"key":"e_1_3_1_49_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2018.03.012"},{"key":"e_1_3_1_50_2","doi-asserted-by":"publisher","DOI":"10.1038\/emboj.2010.63"},{"key":"e_1_3_1_51_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41589-019-0263-0"},{"key":"e_1_3_1_52_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-018-0375-7"},{"key":"e_1_3_1_53_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrd4360"},{"key":"e_1_3_1_54_2","doi-asserted-by":"publisher","DOI":"10.1101\/gad.267278.115"},{"key":"e_1_3_1_55_2","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2017.180844"},{"key":"e_1_3_1_56_2","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-15-2333"},{"key":"e_1_3_1_57_2","doi-asserted-by":"publisher","DOI":"10.1128\/MCB.00467-08"},{"key":"e_1_3_1_58_2","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.aax2746"},{"key":"e_1_3_1_59_2","doi-asserted-by":"publisher","DOI":"10.1038\/nm.2661"},{"key":"e_1_3_1_60_2","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2014.119"},{"key":"e_1_3_1_61_2","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20110540"},{"key":"e_1_3_1_62_2","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20120521"},{"key":"e_1_3_1_63_2","doi-asserted-by":"publisher","DOI":"10.1097\/HS9.0000000000000054"},{"key":"e_1_3_1_64_2","doi-asserted-by":"publisher","DOI":"10.1080\/13543784.2023.2267980"},{"key":"e_1_3_1_65_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-021-00487-3"},{"key":"e_1_3_1_66_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-10-810622"},{"key":"e_1_3_1_67_2","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkw832"},{"key":"e_1_3_1_68_2","doi-asserted-by":"publisher","DOI":"10.1002\/cnr2.1588"},{"key":"e_1_3_1_69_2","first-page":"1","article-title":"JBI-802: the first orally available LSD1\/HDAC6 dual inhibitor to enter clinical trials","author":"Zhang J.","year":"2025","unstructured":"J. Zhang, X. Ren, Y. Song, B. Yu, JBI-802: the first orally available LSD1\/HDAC6 dual inhibitor to enter clinical trials. Expert Opin. Ther. Pat., 1\u20139 (2025).","journal-title":"Expert Opin. Ther. Pat."},{"key":"e_1_3_1_70_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-17913-x"},{"key":"e_1_3_1_71_2","doi-asserted-by":"publisher","DOI":"10.18632\/aging.102887"},{"key":"e_1_3_1_72_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0058957"},{"key":"e_1_3_1_73_2","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202004504"},{"key":"e_1_3_1_74_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-021-03785-7"},{"key":"e_1_3_1_75_2","doi-asserted-by":"publisher","DOI":"10.1038\/nature04020"},{"key":"e_1_3_1_76_2","doi-asserted-by":"publisher","DOI":"10.1038\/embor.2010.62"},{"key":"e_1_3_1_77_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1614664114"},{"key":"e_1_3_1_78_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.1147674"},{"key":"e_1_3_1_79_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.febslet.2005.03.015"},{"key":"e_1_3_1_80_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41594-022-00856-x"},{"key":"e_1_3_1_81_2","doi-asserted-by":"publisher","DOI":"10.1038\/nature11412"},{"key":"e_1_3_1_82_2","doi-asserted-by":"publisher","DOI":"10.3390\/ijms14010108"},{"key":"e_1_3_1_83_2","doi-asserted-by":"publisher","DOI":"10.1677\/erc.1.00776"},{"key":"e_1_3_1_84_2","doi-asserted-by":"publisher","DOI":"10.1124\/mol.105.014514"},{"key":"e_1_3_1_85_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-04-1023"},{"key":"e_1_3_1_86_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1208662"},{"key":"e_1_3_1_87_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-007-9751-0"},{"key":"e_1_3_1_88_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2007.10.035"},{"key":"e_1_3_1_89_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-06-3093"},{"key":"e_1_3_1_90_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.molonc.2014.05.013"},{"key":"e_1_3_1_91_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41388-019-0923-2"},{"key":"e_1_3_1_92_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijbiomac.2020.08.221"},{"key":"e_1_3_1_93_2","first-page":"116","article-title":"TRIM37 is a new histone H2A ubiquitin ligase and breast cancer oncoprotein","volume":"516","author":"Bhatnagar S.","year":"2014","unstructured":"S. Bhatnagar, C. Gazin, L. Chamberlain, J. Ou, X. Zhu, J. S. Tushir, C.-M. Virbasius, L. Lin, L. J. Zhu, N. Wajapeyee, M. R. Green, TRIM37 is a new histone H2A ubiquitin ligase and breast cancer oncoprotein. INature 516, 116\u2013120 (2014).","journal-title":"INature"},{"key":"e_1_3_1_94_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1719168115"},{"key":"e_1_3_1_95_2","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-22-2433"},{"key":"e_1_3_1_96_2","doi-asserted-by":"publisher","DOI":"10.1038\/ncb1668"},{"key":"e_1_3_1_97_2","doi-asserted-by":"publisher","DOI":"10.1038\/nature08839"},{"key":"e_1_3_1_98_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41588-020-0681-7"},{"key":"e_1_3_1_99_2","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000015608"},{"key":"e_1_3_1_100_2","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-16-1174"},{"key":"e_1_3_1_101_2","doi-asserted-by":"publisher","DOI":"10.1038\/nm.4045"},{"key":"e_1_3_1_102_2","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.167440"},{"key":"e_1_3_1_103_2","doi-asserted-by":"crossref","unstructured":"A. Mandl S. Jasmine T. E. G. Krueger R. Kumar I. M. Coleman S. L. Dalrymple L. Antony D. M. Rosen Y. Jing B. Hanratty R. A. Patel L. Jin-Yih J. Dias C. A. Celatka A. E. Tapper M. Kleppe M. Kanayama V. Speranzini Y. Z. Wang J. Luo E. Corey L. A. Sena R. A. Casero T. Lotan B. J. Trock S. K. Kachhap S. R. Denmeade M. A. Carducci A. Mattevi M. C. Haffner P. S. Nelson H. Y. Rienhoff J. T. Isaacs W. N. Brennen LSD1 inhibition suppresses ASCL1 and de-represses YAP1 to drive potent activity against neuroendocrine prostate cancer. bioRxiv [Preprint] (2024); https:\/\/doi.org\/10.1101\/2024.01.17.576106.","DOI":"10.1101\/2024.01.17.576106"},{"key":"e_1_3_1_104_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41391-020-0229-z"},{"key":"e_1_3_1_105_2","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-08-2216"},{"key":"e_1_3_1_106_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2014.11.008"},{"key":"e_1_3_1_107_2","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21708"},{"key":"e_1_3_1_108_2","unstructured":"Canadian Cancer Statistics Advisory Committee in collaboration with the Canadian Cancer Society Statistics Canada and the Public Health Agency of Canada Canadian Cancer Statistics 2023 (2023). http:\/\/cancer.ca\/Canadian-Cancer-Statistics-2023-EN."},{"key":"e_1_3_1_109_2","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2021.0058"},{"key":"e_1_3_1_110_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-019-0133-9"},{"key":"e_1_3_1_111_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2016.06.081"},{"key":"e_1_3_1_112_2","doi-asserted-by":"publisher","DOI":"10.1101\/gad.314815.118"},{"key":"e_1_3_1_113_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-023-06053-y"},{"key":"e_1_3_1_114_2","doi-asserted-by":"publisher","DOI":"10.1002\/1878-0261.13124"},{"key":"e_1_3_1_115_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2015.06.002"},{"key":"e_1_3_1_116_2","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-16-3502"},{"key":"e_1_3_1_117_2","doi-asserted-by":"publisher","DOI":"10.1126\/scisignal.aau2922"},{"key":"e_1_3_1_118_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-31998-7"},{"key":"e_1_3_1_119_2","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.5500-09.2010"},{"key":"e_1_3_1_120_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.molcel.2015.01.010"},{"key":"e_1_3_1_121_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrep.2016.11.015"},{"key":"e_1_3_1_122_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-44348-y"},{"key":"e_1_3_1_123_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2022.05.014"},{"key":"e_1_3_1_124_2","doi-asserted-by":"publisher","DOI":"10.1158\/1541-7786.MCR-21-0310"},{"key":"e_1_3_1_125_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2023021342"},{"key":"e_1_3_1_126_2","unstructured":"S. Mahapatra K. B. Challagundla \u201cNeuroblastoma\u201d in StatPearls (StatPearls Publishing Treasure Island (FL) 2024; http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK448111\/)."},{"key":"e_1_3_1_127_2","first-page":"589","article-title":"Retinoic acid-induced growth inhibition and morphologic differentiation of human neuroblastoma cells in vitro","volume":"68","author":"Sidell N.","year":"1982","unstructured":"N. Sidell, Retinoic acid-induced growth inhibition and morphologic differentiation of human neuroblastoma cells in vitro. J. Natl. Cancer Inst. 68, 589\u2013596 (1982).","journal-title":"J. Natl. Cancer Inst"},{"key":"e_1_3_1_128_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.6719137"},{"key":"e_1_3_1_129_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3526"},{"key":"e_1_3_1_130_2","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-08-1735"},{"key":"e_1_3_1_131_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.molcel.2014.06.006"},{"key":"e_1_3_1_132_2","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.3990"},{"key":"e_1_3_1_133_2","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.12924"},{"key":"e_1_3_1_134_2","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.24035"},{"key":"e_1_3_1_135_2","doi-asserted-by":"publisher","DOI":"10.1007\/s13402-023-00843-4"},{"key":"e_1_3_1_136_2","doi-asserted-by":"publisher","DOI":"10.1038\/nature09542"},{"key":"e_1_3_1_137_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2016.04.012"},{"key":"e_1_3_1_138_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M114.566448"},{"key":"e_1_3_1_139_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41388-020-1268-6"},{"key":"e_1_3_1_140_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.chembiol.2013.03.020"},{"key":"e_1_3_1_141_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41594-023-01041-4"},{"key":"e_1_3_1_142_2","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.1604-11.2011"},{"key":"e_1_3_1_143_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.26145"},{"key":"e_1_3_1_144_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13046-023-02694-1"},{"key":"e_1_3_1_145_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12964-018-0275-5"},{"key":"e_1_3_1_146_2","doi-asserted-by":"publisher","DOI":"10.1128\/mBio.00313-10"},{"key":"e_1_3_1_147_2","unstructured":"T. Kanderi V. Gupta \u201cGlioblastoma Multiforme\u201d in StatPearls (StatPearls Publishing Treasure Island (FL) 2024; http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK558954\/ )."},{"key":"e_1_3_1_148_2","doi-asserted-by":"publisher","DOI":"10.1002\/stem.1020"},{"key":"e_1_3_1_149_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.1192002"},{"key":"e_1_3_1_150_2","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.2681"},{"key":"e_1_3_1_151_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2021.105764"},{"key":"e_1_3_1_152_2","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noad018"},{"key":"e_1_3_1_153_2","doi-asserted-by":"publisher","DOI":"10.1038\/ng.1102"},{"key":"e_1_3_1_154_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2018.11.015"},{"key":"e_1_3_1_155_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2013.10.006"},{"key":"e_1_3_1_156_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2019.09.005"},{"key":"e_1_3_1_157_2","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noaa058"},{"issue":"24","key":"e_1_3_1_158_2","article-title":"DIPG-26. Targeted protein degradation of LSD1 synergizes with HDAC inhibitors in diffuse intrinsic pontine glioma","volume":"24","author":"Groves A.","year":"2022","unstructured":"A. Groves, R. Poetschke, H. Mire, E. Panditharatna, M. T. Guzman, J. Qi, M. Filbin, DIPG-26. Targeted protein degradation of LSD1 synergizes with HDAC inhibitors in diffuse intrinsic pontine glioma. Neuro Oncol. 24, i24 (2022).","journal-title":"Neuro Oncol."},{"key":"e_1_3_1_159_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00401-011-0922-z"},{"key":"e_1_3_1_160_2","doi-asserted-by":"publisher","DOI":"10.1038\/nature13379"},{"key":"e_1_3_1_161_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-08269-5"},{"key":"e_1_3_1_162_2","doi-asserted-by":"publisher","DOI":"10.1186\/s40478-015-0201-7"},{"key":"e_1_3_1_163_2","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noaa191"},{"key":"e_1_3_1_164_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2016.02.011"},{"key":"e_1_3_1_165_2","doi-asserted-by":"publisher","DOI":"10.1038\/nature22973"},{"key":"e_1_3_1_166_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00401-019-01990-5"},{"key":"e_1_3_1_167_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41418-022-00983-4"},{"key":"e_1_3_1_168_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)60111-1"},{"key":"e_1_3_1_169_2","doi-asserted-by":"publisher","DOI":"10.1038\/ng1219"},{"key":"e_1_3_1_170_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.1059581"},{"key":"e_1_3_1_171_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1750-3639.2007.00111.x"},{"key":"e_1_3_1_172_2","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.2390-08.2008"},{"key":"e_1_3_1_173_2","doi-asserted-by":"publisher","DOI":"10.1002\/stem.1430"},{"key":"e_1_3_1_174_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2016.07.149"},{"key":"e_1_3_1_175_2","doi-asserted-by":"publisher","DOI":"10.1093\/hmg\/ddg352"},{"key":"e_1_3_1_176_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1471-4159.2010.06672.x"},{"key":"e_1_3_1_177_2","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.55911"},{"key":"e_1_3_1_178_2","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.23-28-09418.2003"},{"key":"e_1_3_1_179_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0437870100"},{"key":"e_1_3_1_180_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M410210200"},{"key":"e_1_3_1_181_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.pbb.2009.08.001"},{"key":"e_1_3_1_182_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pbio.1002114"},{"key":"e_1_3_1_183_2","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2017.267"},{"key":"e_1_3_1_184_2","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.16-19494"},{"key":"e_1_3_1_185_2","doi-asserted-by":"publisher","DOI":"10.1021\/cb500018s"},{"key":"e_1_3_1_186_2","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.aba1187"},{"key":"e_1_3_1_187_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41386-018-0300-9"},{"key":"e_1_3_1_188_2","doi-asserted-by":"publisher","DOI":"10.1021\/acschemneuro.1c00713"},{"key":"e_1_3_1_189_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0233468"},{"key":"e_1_3_1_190_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2022.175227"},{"key":"e_1_3_1_191_2","doi-asserted-by":"publisher","DOI":"10.1111\/jcmm.17444"},{"key":"e_1_3_1_192_2","doi-asserted-by":"publisher","DOI":"10.2147\/IJN.S200490"},{"key":"e_1_3_1_193_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(15)70016-5"},{"key":"e_1_3_1_194_2","doi-asserted-by":"publisher","DOI":"10.1084\/jem.184.4.1425"},{"key":"e_1_3_1_195_2","doi-asserted-by":"publisher","DOI":"10.1097\/NEN.0b013e318283114a"},{"key":"e_1_3_1_196_2","doi-asserted-by":"publisher","DOI":"10.1038\/nature05772"},{"key":"e_1_3_1_197_2","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.0296-07.2007"},{"key":"e_1_3_1_198_2","doi-asserted-by":"publisher","DOI":"10.1038\/nature10849"},{"key":"e_1_3_1_199_2","doi-asserted-by":"publisher","DOI":"10.1038\/nature07925"},{"key":"e_1_3_1_200_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.expneurol.2012.10.005"},{"key":"e_1_3_1_201_2","doi-asserted-by":"publisher","DOI":"10.1021\/acschemneuro.8b00620"},{"key":"e_1_3_1_202_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2018.05.052"},{"key":"e_1_3_1_203_2","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-20-0017"},{"key":"e_1_3_1_204_2","doi-asserted-by":"publisher","DOI":"10.1038\/nature25501"},{"key":"e_1_3_1_205_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2023.113477"},{"key":"e_1_3_1_206_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41388-018-0451-5"},{"key":"e_1_3_1_207_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-021-03556-4"},{"key":"e_1_3_1_208_2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.01228"},{"key":"e_1_3_1_209_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.1229620"},{"key":"e_1_3_1_210_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-022-00689-z"},{"key":"e_1_3_1_211_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI131375"},{"key":"e_1_3_1_212_2","first-page":"342","article-title":"Vital role of the CoREST complex as a master regulator of Foxp3+ T-regulatory cell gene expression and suppressive function","volume":"17","author":"Wang L.","year":"2017","unstructured":"L. Wang, A. Samanta, M. Levine, U. Beier, R. Han, J. Kalin, E. Holson, P. Cole, W. Hancock, Vital role of the CoREST complex as a master regulator of Foxp3+ T-regulatory cell gene expression and suppressive function. Am. J. Transplant. 17, 342 (2017).","journal-title":"Am. J. Transplant."},{"key":"e_1_3_1_213_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2009.10.037"},{"key":"e_1_3_1_214_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-179329"},{"key":"e_1_3_1_215_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-2380"},{"key":"e_1_3_1_216_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.34366"},{"key":"e_1_3_1_217_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2023.09.251"},{"key":"e_1_3_1_218_2","unstructured":"Celgene. 2023 A Phase 1 Open-label Functional Imaging Study to Assess Whether CC-90011 Reverses the Castration Resistance Due to Lineage Switch in Subjects With Metastatic Castration-resistant Prostate Cancer (mCRPC) Who Have Failed Enzalutamide as Last Prior Therapy Followed by a Dose Finding Study of CC-90011 Combined With Abiraterone and Prednisone (Clinical trial registration NCT04628988 clinicaltrials.gov); https:\/\/clinicaltrials.gov\/study\/NCT04628988."},{"key":"e_1_3_1_219_2","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2021.2012667"},{"key":"e_1_3_1_220_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2019.06.021"},{"key":"e_1_3_1_221_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.03250"},{"key":"e_1_3_1_222_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-168945"},{"key":"e_1_3_1_223_2","unstructured":"Jubilant Therapeutics Inc. Press Releases: JBI-802 initial Phase I data suggests therapeutic potential in sensitizing immunotherapy resistant tumors and in Myeloproliferative Neoplasms with thrombocytosis. https:\/\/www.jubilanttx.com\/pressreleasedetails.aspx?mpgid=1473&pgid=1475&pressid=504."},{"key":"e_1_3_1_224_2","unstructured":"Salarius Pharmaceuticals LLC \u201cPhase 1 Trial of the LSD1 Inhibitor Seclidemstat (SP 2577) With and Without Topotecan and Cyclophosphamide in Patients With Relapsed or Refractory Ewing Sarcoma and Select Sarcomas\u201d (Clinical trial registration NCT03600649 clinicaltrials.gov 2023); https:\/\/clinicaltrials.gov\/study\/NCT03600649."},{"key":"e_1_3_1_225_2","unstructured":"Salarius Pharmaceuticals LLC \u201cPhase 1 Trial of the LSD1 Inhibitor SP-2577 (Seclidemstat) in Patients With Advanced Solid Tumors\u201d (Clinical trial registration NCT03895684 clinicaltrials.gov 2021); https:\/\/clinicaltrials.gov\/study\/NCT03895684."},{"key":"e_1_3_1_226_2","unstructured":"M.D. Anderson Cancer Center \u201cPhase I\/II Study of SP-2577 (Seclidemstat) in Combination With Azacitidine for Patients With Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia\u201d (Clinical trial registration NCT04734990 clinicaltrials.gov 2023); https:\/\/clinicaltrials.gov\/study\/NCT04734990."},{"key":"e_1_3_1_227_2","doi-asserted-by":"crossref","unstructured":"D. R. Reed S. P. Chawla B. Setty L. Mascarenhas P. A. Meyers J. Metts D. J. Harrison D. Loeb B. D. Crompton D. S. Wages D. D. Stenehjem D. Y. Santiesteban N. Q. Mirza S. G. DuBois Phase 1 trial of seclidemstat (SP-2577) in patients with relapsed\/refractory Ewing sarcoma. J. Clin. Oncol. 39 11514\u201311514 (2021).","DOI":"10.1200\/JCO.2021.39.15_suppl.11514"},{"key":"e_1_3_1_228_2","unstructured":"Salarius Pharmaceuticals Inc. Investigator-initiated Phase 1\/2 Clinical Trial Using Salarius Pharmaceuticals\u2019 Seclidemstat in Combination with Azacitidine to Treat Hematologic Cancers Resumes Patient Enrollment | Salarius Pharmaceuticals Inc. https:\/\/investors.salariuspharma.com\/news-releases\/news-release-details\/investigator-initiated-phase-12-clinical-trial-using-salarius."},{"key":"e_1_3_1_229_2","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.14912"},{"key":"e_1_3_1_230_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-020-0892-z"},{"key":"e_1_3_1_231_2","doi-asserted-by":"crossref","unstructured":"L. Ahronian X. Wu M. Zhang C. Min A. Tsai J. Ermolieff P. McCarren M. Wyman Y. Wang A. Bejnood K. Amemiya B. McMillan N. Das B. Doyon A. Mignault C. Liang V. Elitzin Y. Yu S. Meier A. Choi J. Maxwell A. Huang 444 TNG260 a CoREST-selective deacetylase inhibitor reverses anti-PD1 resistance driven by loss of STK11 in Regular and Young Investigator Award Abstracts (BMJ Publishing Group Ltd. 2022); https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2022-SITC2022.0444 pp. A464\u2013A464.","DOI":"10.1136\/jitc-2022-SITC2022.0444"},{"key":"e_1_3_1_232_2","unstructured":"Oryzon Genomics S.A. ORYZON Announces Topline Results from Phase IIb PORTICO study of vafidemstat in Borderline Personality Disorder (BPD) | Oryzon; https:\/\/oryzon.com\/en\/news-events\/news\/oryzon-announces-topline-results-phase-iib-portico-study-vafidemstat-borderline."},{"key":"e_1_3_1_233_2","unstructured":"Oryzon Genomics S.A. ORYZON presents vafidemstat 12-month clinical data from its Phase IIa clinical trials ETHERAL and REIMAGINE-AD in Alzheimer\u2019s at the virtual AD\/PD-2021 conference | Oryzon; https:\/\/oryzon.com\/en\/news-events\/news\/oryzon-presents-vafidemstat-12-month-clinical-data-its-phase-iia-clinical-trials."},{"key":"e_1_3_1_234_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(19)30202-9"},{"key":"e_1_3_1_235_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2022.03.016"},{"key":"e_1_3_1_236_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2020.09.031"},{"key":"e_1_3_1_237_2","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2023010599"},{"key":"e_1_3_1_238_2","doi-asserted-by":"crossref","unstructured":"F. Milano 1040 Infusion of UM171-Expanded Cord Blood Led to Excellent Survival in Patients with High-Risk Leukemias: Results from Two Independent Phase II Studies (65th ASH Annual Meeting & Exposition 2023); https:\/\/ash.confex.com\/ash\/2023\/webprogram\/Paper187446.html.","DOI":"10.1182\/blood-2023-187446"},{"key":"e_1_3_1_239_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-019-0659-6"},{"key":"e_1_3_1_240_2","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2019.224501"},{"key":"e_1_3_1_241_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-09-807024"},{"key":"e_1_3_1_242_2","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.26326"},{"key":"e_1_3_1_243_2","doi-asserted-by":"publisher","DOI":"10.1158\/1541-7786.MCR-22-0027"},{"key":"e_1_3_1_244_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41588-020-0702-6"},{"key":"e_1_3_1_245_2","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2019.243121"},{"key":"e_1_3_1_246_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-180924"},{"key":"e_1_3_1_247_2","first-page":"941","article-title":"P1051: A phase 2 study of imG-7289 (BOMEDEMSTAT) in patients with advanced myelofibrosis","volume":"6","author":"Gill H.","year":"2022","unstructured":"H. Gill, A. Yacoub, K. Pettit, T. Bradley, A. Gerds, M. Tatarczuch, J. Shortt, N. Curtin, J. Rossetti, K. Burbury, A. Mead, J. G\u00f6thert, S. Koschmieder, A. Jones, J. Peppe, J. Dias, G. Natsoulis, T. McClure, M. Kleppe, W.-J. Hong, W. Stevenson, J. Ewing, J. Chacko, E. Rumi, A. Halpern, F. Palandri, N. Vianelli, F. Passamonti, R. Mesa, M. Marchetti, C. Harrison, A. Vannucchi, J. Watts, D. Ross, M. Talpaz, H. Rienhoff, P1051: A phase 2 study of imG-7289 (BOMEDEMSTAT) in patients with advanced myelofibrosis. Hema 6, 941\u2013942 (2022).","journal-title":"Hema"},{"key":"e_1_3_1_248_2","unstructured":"Imago BioSciences Inc. a subsidiary of Merck & Co. Inc. (Rahway New Jersey USA). 2023 \u201cA Multi-Center Open Label Study to Assess the Safety Steady-State Pharmacokinetics and Pharmacodynamics of IMG-7289 in Patients With Myelofibrosis\u201d (Clinical trial registration NCT03136185 clinicaltrials.gov 2023); https:\/\/clinicaltrials.gov\/study\/NCT03136185."},{"key":"e_1_3_1_249_2","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.862427"},{"key":"e_1_3_1_250_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2021.39.15_suppl.3073"},{"key":"e_1_3_1_251_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-4054"},{"key":"e_1_3_1_252_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-159471"},{"key":"e_1_3_1_253_2","unstructured":"ORYZON ORYZON presents the final data from PORTICO a global Phase IIb vafidemstat trial in Borderline Personality Disorder (BPD) at the European College of Neuropsycopharmacology (ECNP) congress; https:\/\/oryzon.com\/en\/news-events\/news\/oryzon-presents-final-data-portico-global-phase-iib-vafidemstat-trial-borderline."}],"container-title":["Science Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.science.org\/doi\/pdf\/10.1126\/sciadv.ads6556","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,11]],"date-time":"2025-06-11T15:24:22Z","timestamp":1749655462000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.science.org\/doi\/10.1126\/sciadv.ads6556"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,6]]},"references-count":252,"journal-issue":{"issue":"23","published-print":{"date-parts":[[2025,6,6]]}},"alternative-id":["10.1126\/sciadv.ads6556"],"URL":"https:\/\/doi.org\/10.1126\/sciadv.ads6556","relation":{},"ISSN":["2375-2548"],"issn-type":[{"value":"2375-2548","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,6]]},"assertion":[{"value":"2024-08-23","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-05-02","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-06-06","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"eads6556"}}